Fate Therapeutics (FATE) Accumulated Expenses (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Accumulated Expenses came in at $13.6 million in Q1 2026, down 20.75% YoY from $17.2 million in Q1 2025, and down 31.87% on a QoQ basis from $20.0 million in Q4 2025.
Fate Therapeutics (FATE) Accumulated Expenses (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Accumulated Expenses data on file, last reported at $13.6 million in Q1 2026.
- Quarterly Accumulated Expenses fell 20.75% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 20.75% YoY) and the FY2025 annual result came in at $20.0 million, up 106.22% from the prior year.
- Accumulated Expenses retreated to $13.6 million in Q1 2026, from $20.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $53.9 million in Q4 2022 to a low of $5.4 million in Q1 2024.
- A 5-year average of $20.4 million and a median of $17.4 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 319.32% — and 2024, when it sank 82.82%.
- Tracing FATE's Accumulated Expenses over 5 years: stood at $53.9 million in 2022, then sank by 48.98% to $27.5 million in 2023, then plunged by 64.71% to $9.7 million in 2024, then soared by 106.22% to $20.0 million in 2025, then slumped by 31.87% to $13.6 million in 2026.
- The last three Accumulated Expenses figures came in at $13.6 million (Q1 2026), $20.0 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.64 Mn |
| Dec 31, 2025 | 20.02 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 7.12 Mn |
| Mar 31, 2025 | 17.21 Mn |
| Dec 31, 2024 | 9.71 Mn |
| Sep 30, 2024 | 23.58 Mn |
| Jun 30, 2024 | 22.65 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Dec 31, 2023 | 27.51 Mn |
| Sep 30, 2023 | 9.06 Mn |
| Jun 30, 2023 | 29.47 Mn |
| Mar 31, 2023 | 31.51 Mn |
| Dec 31, 2022 | 53.93 Mn |
| Sep 30, 2022 | 17.40 Mn |
| Jun 30, 2022 | 16.55 Mn |
| Mar 31, 2022 | 35.11 Mn |
| Dec 31, 2021 | 42.41 Mn |
| Sep 30, 2021 | 54.00 Mn |
| Jun 30, 2021 | 25.74 Mn |